Skip to main content

Table 1 Gastrointestinal stromal tumor manifestation before start of systemic therapy

From: Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

 

n = 55

Synchronous disease

n = 21

Stomach + hepatic metastasis

6

Small intestine + hepatic metastasis

2

Colon + hepatic metastasis

1

Stomach + peritoneal metastasis

5

Duodenum + peritoneal metastasis

2

Small intestine + peritoneal metastasis

3

Rectum + peritoneal metastasis

1

Colon + hepatic and peritoneal metastasis

1

Metachronous disease

n = 34

Peritoneal metastasis

18

Hepatic metastasis

13*

Peritoneal and hepatic metastasis

3

Mutation analysis

n = 33

KIT exon 9 +/− exon 17

6

KIT exon 11 +/− exon 17

16

KIT exon 9 +/− exon 11

1

KIT exon 13

2

KIT exon 17

1

PDGFRA exon 12

1

PDGFRA exon 18

1

wildtype

5

  1. *One patient had concurrent hepatic metastasis and metastasis in left vastus medialis muscle. KIT, tyrosine kinase receptor; PDGFRA, platelet-derived growth factor receptor alpha.